Small molecule HDAC inhibitors: Promising agents for breast cancer treatmentMeiling Huang, Rui Ling, Juliang Zhang et al.|Bioorganic Chemistry|2019Cited by 76
A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (<scp>CBCRT</scp>01)Jianghao Chen, Ling Wang, Jing Wang et al.|International Journal of Cancer|2017Cited by 30